News May 21, 2026

Retatrutide TRIUMPH-1: Lilly's New Phase 3 Obesity Data Just Raised the Bar Again

On May 21, 2026, Eli Lilly announced TRIUMPH-1 Phase 3 results for retatrutide. The topline showed 28.3% mean weight loss at 80 weeks, plus an unusually large share of participants reaching 30% or greater weight loss.

Eli Lilly just delivered one of the biggest obesity-drug headlines of 2026.

On May 21, 2026, the company announced positive topline results from TRIUMPH-1, its pivotal Phase 3 obesity trial of retatrutide.¹

The headline number is hard to miss:

28.3% mean weight loss at 80 weeks on 12 mg

But the more historically important number may be this one:

45.3% of participants on 12 mg achieved 30% or greater weight loss¹

That is the threshold Lilly itself framed as a level long associated with bariatric surgery.¹

This is not FDA approval.

And these are still topline data, not a full peer-reviewed publication.

But as of May 21, 2026, retatrutide has now produced the strongest late-stage obesity efficacy signal publicly reported by a major drugmaker.

What retatrutide is

Retatrutide, also known as LY3437943, is Lilly’s investigational once-weekly triple hormone receptor agonist.¹²

It activates three receptors in one molecule:

GLP-1
GIP
glucagon

That third receptor is what makes retatrutide different from the current blockbuster obesity drugs most people already know.

semaglutide targets GLP-1
tirzepatide targets GIP + GLP-1
retatrutide targets GIP + GLP-1 + glucagon

Lilly has argued for a while that adding glucagon receptor agonism may help push weight loss beyond what the earlier generations can do.³⁴

The simplified version is:

GLP-1 helps reduce appetite
GIP appears to contribute to the overall metabolic effect and may help with tolerability and insulin biology
glucagon may help increase energy expenditure and lipid oxidation

That does not mean we can assign precise percentages of retatrutide’s benefit to each receptor today.

But it does mean the drug was designed to do more than simply suppress food intake.

What TRIUMPH-1 actually tested

TRIUMPH-1 is a Phase 3, 80-week, randomized, double-blind, placebo-controlled trial in adults with:

obesity
or overweight plus at least one weight-related comorbidity
and without diabetes¹⁵

Lilly says the trial randomized 2,339 participants in a 1:1:1:1 ratio to:

retatrutide 4 mg
retatrutide 9 mg
retatrutide 12 mg
or placebo¹

The reported average baseline weight was 112.7 kg (248.5 lbs) and the average baseline BMI was 40.0 kg/m2.¹

That is important context.

This was not a cosmetic-weight-loss study.

This was a late-stage obesity program in a population with severe baseline disease burden.

The new Phase 3 efficacy numbers

According to Lilly’s May 21, 2026 release, the primary endpoint at 80 weeks showed the following mean body-weight changes:

4 mg: -19.0% (-47.2 lbs)
9 mg: -25.9% (-64.4 lbs)
12 mg: -28.3% (-70.3 lbs)
placebo: -2.2% (-5.5 lbs)¹

That is already enough to make the trial one of the most important obesity readouts of the year.

But the responder analyses are what make the data feel historically different.

At 80 weeks, Lilly reported that participants on 12 mg achieved:

62.5% reaching 25% or greater weight loss
45.3% reaching 30% or greater weight loss
27.2% reaching 35% or greater weight loss¹

Those are unusually large responder rates for any anti-obesity medicine, especially in a pivotal trial.

The “no longer obese” finding may be the cleanest headline for the public

One of the most striking results in the release is not just the average percentage lost.

It is what happened to participants’ BMI categories.

Lilly reported that 65.3% of participants on 12 mg reached BMI <30 by week 80.¹

That means nearly two-thirds of people on the top dose dropped below the clinical obesity threshold.

The more dramatic subgroup result is even harder to ignore:

37.5% of participants who started with class 3 obesity (BMI >=40) also ended up below BMI 30.¹

That is one of the cleanest “obesity reversal” style findings any late-stage obesity drug has reported so far.

It should still be interpreted carefully.

BMI thresholds are blunt tools, and dropping below a category line is not the same thing as curing the underlying chronic disease.

But as a public-health and clinical-communication milestone, it is a very powerful result.

The 104-week extension matters too

Lilly also reported results from a pre-specified blinded extension in participants who had:

baseline BMI >=35
completed the 80-week main study
and tolerated their assigned dose¹

This extension enrolled 532 participants.¹

At 104 weeks, the reported mean body-weight changes were:

4 mg to maximum tolerated dose: -27.9%
9 mg to maximum tolerated dose: -29.5%
12 mg to maximum tolerated dose: -30.3%
placebo to retatrutide maximum tolerated dose: -19.2%¹

The 12 mg extension group lost an average of 85.0 lbs.¹

That does not mean everyone with obesity will lose 30% of body weight on retatrutide.

But it does show that in a particularly high-BMI subgroup that stayed on treatment and tolerated therapy, weight loss continued to deepen over time.

The tolerability story is strong, but it needs careful wording

This is the part that is easiest to overstate.

It would be inaccurate to say today’s data prove there were no cardiac signals or no liver signals.

Lilly did not release that kind of comprehensive safety claim in the topline announcement.

What Lilly did say is that retatrutide showed significant improvements from baseline in certain cardiometabolic risk markers, including:

waist circumference
non-HDL cholesterol
triglycerides
systolic blood pressure
and high-sensitivity C-reactive protein (hsCRP)¹

That is a meaningful positive finding.

But it is not the same thing as a full long-term cardiac or hepatic safety verdict.

The adverse-event profile Lilly did release was more specific.

The most common adverse events were described as broadly consistent with incretin-class therapy, including:

nausea
diarrhea
constipation
vomiting
plus some higher rates of dysesthesia and urinary tract infection versus placebo¹

Lilly reported discontinuations due to adverse events of:

4.1% at 4 mg
6.9% at 9 mg
11.3% at 12 mg
versus 4.9% with placebo¹

That 12 mg discontinuation rate is not trivial.

But it is also better than many people feared after the earlier TRIUMPH-4 readout in obesity with knee osteoarthritis.

Why TRIUMPH-1 tolerability may matter even more than the weight-loss headline

In TRIUMPH-4, Lilly previously reported 28.7% mean weight loss at 68 weeks on 12 mg, but the trial also drew attention for its more challenging tolerability profile.⁶

TRIUMPH-1 looks better on that front.

The most practical reason may be that Lilly now has a clearer dose-escalation story.

The 4 mg arm in TRIUMPH-1 is especially interesting because participants got there with only one escalation step and still lost an average of 19.0% body weight, with a discontinuation rate that was actually below placebo in the topline table.¹

That is important because it suggests retatrutide may not be a one-setting drug.

There may be a meaningful clinical spectrum between:

a lower-discontinuation, still-high-efficacy dose
and the highest, most aggressive weight-loss dose

That is the kind of detail that can matter a lot in real-world practice.

Why this matters in the bigger obesity-drug race

Retatrutide’s new data raise the bar again.

In broad context:

Wegovy (semaglutide) changed the market by pushing average weight loss into the mid-teens
Zepbound (tirzepatide) pushed average Phase 3 weight loss above 20%
retatrutide is now pushing topline late-stage obesity results toward 30%

That does not make cross-trial comparisons perfect.

Trial populations, durations, endpoints, and dose-escalation designs differ.

But it does make one point very hard to deny:

retatrutide is now the late-stage obesity asset most likely to define the next performance standard in the category.

And because it is still investigational, Lilly now has something strategically powerful:

a marketed obesity leader in tirzepatide
and a next-wave candidate in retatrutide that may push efficacy even further

What happens next

The most important limitation in today’s news is simple:

these are topline data.

Detailed results still need to be presented at scientific meetings and published in a peer-reviewed paper.¹

Lilly said more TRIUMPH results will be shared later in 2026, including:

TRIUMPH-2 in obesity or overweight with type 2 diabetes
TRIUMPH-3 in obesity or overweight with established cardiovascular disease¹

Axios also reported on May 21, 2026 that if the remaining late-stage trials are successful, Lilly plans to move toward FDA submission as early as the end of the year.⁴

That is not the same thing as approval.

But it does tell you how important Lilly thinks this program is now.

The bottom line

The cleanest fair summary of TRIUMPH-1 today is:

retatrutide just produced 28.3% mean weight loss at 80 weeks
45.3% of participants on 12 mg reached 30% or greater weight loss
65.3% fell below the BMI 30 obesity threshold
and 37.5% of those starting with class 3 obesity also got below that threshold¹

That is a major obesity-drug milestone.

The safety story is promising, but not fully settled from a topline release alone.

The efficacy story, though, is already clear:

retatrutide just made the next phase of the obesity-drug race look even more competitive.